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ABSTRACT
Context Whether immunosuppressive treatment
adversely affects survival is unclear.
Objective To assess whether immunosuppressive drugs
increase mortality.
Design Retrospective cohort study evaluating overall and
cancer mortality in relation to immunosuppressive drug
exposure among patients with ocular inflammatory
diseases. Demographic, clinical, and treatment data
derived from medical records, and mortality results from
United States National Death Index linkage. The cohort’s
mortality risk was compared with US vital statistics using
standardised mortality ratios. Overall and cancer
mortality in relation to use or non-use of
immunosuppressive drugs within the cohort was studied
with survival analysis.
Setting Five tertiary ocular inflammation clinics.
Patients 7957 US residents with non-infectious ocular
inflammation, 2340 of whom received
immunosuppressive drugs during follow up.
Exposures Use of antimetabolites, T cell inhibitors,
alkylating agents, and tumour necrosis factor inhibitors.
Main outcome measures Overall mortality, cancer
mortality.
Results Over 66802 person years (17316 after exposure
to immunosuppressive drugs), 936 patients died (1.4/
100 person years), 230 (24.6%) from cancer. For patients
unexposed to immunosuppressive treatment, risks of
death overall (standardised mortality ratio 1.02, 95%
confidence interval [CI] 0.94 to 1.11) and from cancer
(1.10, 0.93 to 1.29) were similar to those of the US
population. Patients who used azathioprine,
methotrexate, mycophenolate mofetil, ciclosporin,
systemic corticosteroids, or dapsone had overall and
cancermortalitysimilartothatofpatientswhonevertook
immunosuppressive drugs. In patients who used
cyclophosphamide, overall mortality was not increased
and cancer mortality was non-significantly increased.
Tumour necrosis factor inhibitors were associated with
increasedoverall(adjustedhazardratio[HR]1.99,95%CI
1.00 to 3.98) and cancer mortality (adjusted HR 3.83,
1.13 to 13.01).
Conclusions Most commonly used immunosuppressive
drugs do not seem to increase overall or cancer mortality.
Our results suggesting that tumour necrosis factor
inhibitors might increase mortality are less robust than
the other findings; additional evidence is needed.
INTRODUCTION
A common dilemma faced by patients with inflamma-
torydiseasesiswhetherthe benefitsofsystemicimmu-
nosuppressive therapywarranttheassociatedrisks.Of
particular concern is the possibility of inducing a life
threatening illness, such as cancer, in the process of
achievingsymptomaticbenefits.Accurateinformation
about the true extent of long term risks with such ther-
apy is needed to inform clinical decision making for
these patients. Observational studies—which provide
mostoftheavailableevidenceonthetopic—arepoten-
tiallysubjecttoindications-for-treatmentbias,because
the conditions serving as the indication for immuno-
suppression are themselves often associated with an
intrinsically higher risk of mortality or cancer, and
the patients with more severe disease are more likely
to receive the treatment.
1
Available reports about the risk of mortality after
immunosuppressivetherapyoutsidethetransplantset-
ting are limited. A study of several hundred patients
with rheumatoid arthritis treated with ciclosporin
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this drug.
2 One large observational study of patients
with rheumatoid arthritis found no increased risk of
overall mortality with tumour necrosis factor (TNF)
inhibitors;
3anotherreportednoincreasedriskofover-
all or cancer associated mortality.
4 Findings of studies
in patients with rheumatoid arthritis differ about
whether use of corticosteroids increases
5-8 or does not
increase
910mortality risk.
More information is available about the risk of can-
cerafterimmunosuppressivetreatment.
1Theweightof
evidence suggests that use of azathioprine and metho-
trexate for inflammatory diseases does not substan-
tially increase the overall risk of cancer; the limited
information about mycophenolate mofetil is also
encouraging. Data about T cell inhibitors are limited
outsidethetransplantsetting.Onereportsuggestedno
increased overall risk of cancer among patients with
rheumatoid arthritis,
2 whereas results in patients with
psoriasis indicated a higher risk of leukaemia and of
non-melanomatous skin cancers,
11 which might be
relatedtopotentiationoftheadverseeffectsofpsoralen
andultravioletAtreatmentbyciclosporin.
1Strongevi-
dence exists for increased risk of skin, haematological,
and (for cyclophosphamide) bladder cancers in con-
nection with alkylating agents,
1 and a few reports
have indicated that mortality from all types of cancer
isincreasedfollowingtreatmentwithsuchdrugs.
1213A
meta-analysisofpatientswithrheumatoidarthritisran-
domised to TNF inhibitor therapy in clinical trials
found a 3.3-fold higher risk of cancer over
22-54 weeks’ follow-up.
14 However, several large
observational studies following patients with rheuma-
toidarthritisoversubstantiallylongerperiods
315-17and
one study of patients with Crohn’s disease found no
increased overall risk of cancer.
18
Non-infectious ocular inflammatory diseases pro-
vide a model system wherein the disease serving as
the indication for immunosuppression seems unlikely
to confer an increased risk of cancer or mortality,
potentially avoiding the problem of indications-for-
treatment bias. Here we report the primary results of
a large scale retrospective cohort study evaluating the
relation between immunosuppressive treatments and
mortalityinthesepatients—theSystemicImmunosup-
pressiveTherapyforEyediseases(SITE)cohortstudy.
METHODS
The SITE cohort study methods have been described
in detail previously.
19 Briefly, all eligible patients seen
at five academic ocular inflammation practices in the
United States during the years 1979-2005 contributed
to this analysis. The time period was selected based on
the years covered by the National Death Index at the
timeofthestudy.Eligiblepatientshadanon-infectious
ocular inflammatory diagnosis (uveitis, scleritis, cica-
trising conjunctivitis of mucous membrane pemphi-
goid, and other conjunctival, corneal, optic nerve,
and orbital inflammatory diseases). Patients known to
haveHIVinfectionwereexcluded.Patientsdiagnosed
with cancer before cohort entry were excluded from
the primary within cohort survival analyses, but were
included for comparisons with the United States gen-
eral population (which includes people with pre-exist-
ing cancer).
The centres directly managed immunosuppression
in most instances, and kept detailed records that were
availableforreview.Dataaboutdemographic,clinical,
andtreatmentcharacteristicswereobtainedfrommed-
ical records by a structured, protocol-driven review of
every visit of every patient. At four centres, all eligible
patients identified were studied. At the fifth centre,
because of a larger volume of patients and limited
resources, a random sample of about 40% of the eligi-
ble patients were studied, oversampling subgroups
likely to have received immunosuppression and
patients treated early in the period of observation,
19
soastomaximisetheinformationgainedaboutimmu-
nosuppression and mortality. Reviews were done by
five residency trained ophthalmologists with masters
level or higher epidemiology training and one highly
experiencedophthalmictechnicianandresearchcoor-
dinator. Use of immunosuppressive agents before
cohort entry was noted along with the dosages of
immunosuppressive agents and corticosteroids at all
clinic visits. The broad range of additional data collec-
tion has been described previously.
19 Quality control
features built into the data system required immediate
correctionorverificationofunlikelyvalues.Recordsof
patients who had been seen at more than one of the
participating centres were merged.
Dataonmortalityincidenceduring1979-2005inclu-
sive were obtained by linkage of patient identifiers to
the US National Death Index,
20 which provides near
perfect ascertainment of mortality when US social
security numbers are available (as in about 90% of our
cohort).
2122 Ascertainment of mortality using this
approach is outstanding even based on the other iden-
tifiers we used.
21 Perfect matches on social security
number, all names, and date of birth were accepted as
matches. Possible matches with inconsistencies or
missing values in one or more of these fields were
manually reviewed, and adjudicated by consensus.
Causes of death were obtained using the National
Death Index “plus” feature, extracted from death cer-
tificates in the same manner as for US vital statistics,
which has 96% code-recode reproducibility.
23 Return
of cancer codes (international classification of disease
[ICD]-9 codes 140.0 to 208.9, 239.0 to 239.9, or ICD-
10 codes C00 to C97) as the cause of death were taken
as indicating a cancer death, within which return of
lymphoma codes (ICD-9 codes 200.0 to 202.9 or
ICD-10codesC81.0toC85.9)weretakenasindicating
a lymphoma death.
The study was approved by the participating cen-
tres’ institutional review boards, each of which
approved waiver of consent for this retrospective
study, and also was approved by the National Death
Indexreviewboard.Thestudywasconductedincom-
pliance with the Declaration of Helsinki.
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Person time at risk of mortality was calculated begin-
ning from 1 January 1979 or the first study centre visit
(whicheverwaslater)andendingateitherthe person’s
death or 31 December 2005, the last day on which
death could have been detected. Person time before
use of any immunosuppressive drug was counted
with the unexposed group, whereas person time dur-
ing or after use of an immunosuppressant was counted
in that exposure group. Patients who were started on
oneormoreadditionalimmunosuppressivedrugscon-
tinued to be counted as exposed to the first immuno-
suppressivedrugtotheendoffollow-up,andalsowere
counted as exposed to the additional drugs from the
point of starting the additional drugs onwards. Cumu-
lative and highest observed doses and duration of
observed therapy were calculated.
To compare mortality in the cohort with that in the
general population, US vital statistics mortality data
(wonder.cdc.gov, accessed on 18 February 2009)
were downloaded within strata of sex, race, and age
(using five year age bands). Cohort data were sorted
into the same strata, whence standardised mortality
ratios(SMRs)and standardisedcancer mortality ratios
were calculated to make the comparison of mortality
experience, adjusted for age, race, and sex.
For the within cohort survival analysis, Cox
regression
24 was used to adjust for potentially con-
founding variables: age, race, sex, smoking status, site
ofocularinflammation,systemicinflammatorydisease
diagnoses,bilateralocularinflammation,andotherco-
morbidities as indicated by the Charlson index, which
assigns points based on the presence and severity of
systemicdiseases.
25Thecategoriespresentedintable 1
were used for categorical variables. Cox models were
developedforeachimmunosuppressive agent,and for
each class of agents, by forward stepwise selection
amongthecovariatesabove(usingtheWaldχ
2statistic,
p≤0.05), but forcing the primary site of ocular inflam-
mation into each model. Cox models evaluating quar-
tiles and log transformed quantitative levels of both
cumulative dose and highest observed dose also were
constructed. All statistical analyses were done with
SAS version 9.1 (SAS Corporation, Cary, NC).
RESULTS
During 1979-2005 inclusive, 10885 patients meeting
eligibility criteria were seen at the five participating
centres and identified by reviewing all charts (fig 1).
At the largest centre, where a random sample of
patients was studied, 2715 were not sampled, and
hence were excluded. Two hundred and thirteen
more were resident outside the United States, beyond
the reach of the National Death Index. The remaining
7957 were observed over 68751 visits, spanning
14910 person years at the clinical centres. Of these,
2340weretreatedwithimmunosuppressivedrugsdur-
ing observation at the clinical centres. Follow-up for
mortality using the National Death Index to the end
of 2005 covered 66802 person years, including
49486personyearsunexposedtoimmunosuppressive
drugsand17316personyearsoftimeafterexposureto
immunosuppressants.
Table 1 shows presenting characteristics of the
cohort. Because the analysis of exposure was time
dependent, with patients moving from the unexposed
toexposedgroups,fixedcharacteristicsofeachpatient
who contributed person time to each exposure cate-
goryare includedineverycategorytowhichtheycon-
tributed. The median age at presentation was older
among patients who were treated with alkylating
agents (53.8 years) and dapsone (70.5 years), drugs
that were often used for mucous membrane pemphi-
goid with ocular involvement (usually a disease of the
elderly). The distribution of sexes across treatment
groupsreflectedthegreaterfrequencyofocularinflam-
mation among females than among males. The fre-
quency of treatment with antimetabolites and T cell
inhibitors was similar across racial and ethnic groups,
but white people were more commonly treated with
alkylating agents, dapsone, and TNF inhibitors than
other groups. Smoking status was similar across most
treatment groups, but smoking was less common
among patients treated with dapsone. Co-morbidity,
as indicated by the Charlson index, was greatest in
patients treated with TNF inhibitors or alkylating
agents, and was least in patients who did not receive
immunosuppression. Omitting mucous membrane
pemphigoid itself, systemic inflammatory diseases
were associated with ocular inflammation in 1986
patients (25.0%), the most common conditions being
sarcoidosis (5.6%), juvenile idiopathic arthritis (3.8%),
ankylosing spondylitis (3.7%), and rheumatoid arthri-
tis (3.4%) (see supplemental table 1). Systemic inflam-
matory disease co-morbidity was less frequent among
patients who never received immunosuppressive
drugs (21.9%) than in those who were exposed to the
drugs. Nevertheless, only a minority of patients who
were exposed to the drugs had associated systemic
inflammatory diseases—with the exception of those
who received TNF inhibitors (74.2%).
During follow-up, 936 deaths occurred, 230 (24.6%)
of which were attributed to cancer. Of these, 323
deaths occurred in patients exposed to immunosup-
pressive drugs and 613 in unexposed patients. The
cohort’s overall mortality risk—adjusted only for age,
Patients meeting eligibility criteria (n=10 885)
Sampled patients meeting
eligibility criteria (n=8170)
Excluded: patients randomly
selected for exclusion at
one centre (n=2715)
Patients included in study
(n=7 957) (68 751 visits over
14 910 person years directly
observed; 66 902 person
years of follow up for mortality
using national death index)
Excluded: residents of foreign
countries (beyond reach
of national death index)
(n=213)
Fig 1 | Study profile
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Antimetabolites T cell inhibitors
Alkylating
agents TNF inhibitors Dapsone None All patients*
Number of patients contributing person time 1634 775 486 213 255 6819 7957
Age, years; median (range) 45.4 (2.8-93.6) 37.8 (3.2-86.3) 53.8 (5.4-91.4) 41.4 (3.2-79.2) 70.5 (14.0-92.4) 43.6 (2.1-96.9) 43.9 (2.1-96.9)
Sex
Male 559 (34.2) 305 (39.4) 208 (42.8) 77 (36.2) 93 (36.5) 2534 (37.2) 2961 (37.2)
Female 1075 (65.8) 470 (60.6) 278 (57.2) 136 (63.8) 162 (63.5) 4285 (62.8) 4996 (62.8)
Race
White 1276 (78.1) 587 (75.7) 404 (83.1) 173 (81.2) 238 (93.3) 5068 (74.3) 5972 (75.1)
Black/African American 185 (11.3) 110 (14.2) 46 (9.5) 14 (6.6) 5 (2.0) 969 (14.2) 1077 (13.5)
Hispanic 66 (4.0) 26 (3.4) 15 (3.1) 12 (5.6) 9 (3.5) 204 (3.0) 246 (3.1)
Other 68 (4.2) 37 (4.8) 15 (3.1) 13 (6.1) 3 (1.2) 284 (4.2) 339 (4.3)
Missing 39 (2.4) 15 (1.9) 6 (1.2) 1 (0.47) 0 294 (4.3) 323 (4.1)
Smoking
Never 965 (59.1) 370 (47.7) 266 (54.7) 125 (58.7) 162 (63.5) 3915 (57.4) 4551 (57.2)
Former 207 (12.7) 85 (11.0) 69 (14.2) 31 (14.6) 21 (8.2) 874 (12.8) 1020 (12.8)
Current 254 (15.5) 165 (21.3) 83 (17.1) 33 (15.5) 12 (4.7) 1194 (17.5) 1363 (17.1)
Missing 208 (12.7) 155 (20.0) 68 (14.0) 24 (11.3) 60 (23.5) 836 (12.3) 1023 (12.9)
Charlson index
25 score
0 724 (44.4) 392 (50.6) 173 (35.6) 56 (26.3) 87 (34.1) 4291 (63.0) 4781 (60.1)
1 502 (30.8) 201 (26.0) 142 (29.2) 95 (44.6) 74 (29.0) 1371 (20.1) 1730 (21.8)
≥2 406 (24.9) 181 (23.4) 171 (35.2) 62 (29.1) 94 (36.9) 1153 (16.9) 1441 (18.1)
Diagnosis with malignancy before cohort entry† 71 (4.3) 19 (2.5) 29 (6.0) 7 (3.3) 17 (6.7) 327 (4.8) 374 (4.7)
Type of ocular inflammation
Anterior uveitis 368 (22.5) 137 (17.7) 33 (6.8) 68 (31.9) 3 (1.2) 2626 (38.5) 2877 (36.2)
Intermediate uveitis 270 (16.5) 194 (25.0) 24 (4.9) 32 (15.0) 6 (2.4) 1490 (21.9) 1655 (20.8)
Posterior or panuveitis 517 (31.6) 341 (44.0) 114 (23.5) 45 (21.1) 7 (2.7) 1500 (22.0) 1831 (23.0)
Scleritis 245 (15.0) 55 (7.1) 99 (20.4) 56 (26.3) 7 (2.7) 769 (11.3) 937 (11.8)
Ocular mucous membrane pemphigoid 161 (9.9) 25 (3.2) 165 (34.0) 3 (1.4) 227 (89.0) 282 (4.1) 453 (5.7)
Other‡ 73 (4.5) 23 (3.0) 51 (10.5) 9 (4.2) 5 (2.0) 152 (2.2) 204 (2.6)
Bilateral ocular inflammation 1360 (83.2) 681 (87.9) 396 (81.5) 171 (80.3) 243 (95.3) 4731 (69.4) 5677 (71.4)
Systemic inflammatory diseases§ 648 (39.7) 235 (30.3) 185 (38.1) 158 (74.2) 33 (12.9) 1491 (21.9) 1986 (25.0)
Follow-up time for mortality, years: median (IQR) 4.8 (2.44-8.2) 7.6 (3.57-13.7) 7.4 (3.63-12.5) 2.8 (1.68-4.2) 8.8 (4.51-13.5) 5.9 (2.08-11.4) 7.1 (3.59-12.2)
Follow-up time for mortality, person years 9695 7059 4222 692 2450 49486 66802
Follow-up time at clinics, person years 3885 2500 1779 360 891 8431 14810
Total deaths 169 73 125 11 101 613 936
Duration of immunosuppressive treatment, years;
median (IQR)
1.4 (0.5-2.7) 1.5 (0.4-3.5) 0.9 (0.3-1.6) 1.2 (0.4-2.0) 0.7 (0.2-2.5)
Use of other classes of immunosuppressive drugs¶
0 c l a s s e s u s e d 0 0000 5 6 1 7 ( 8 2 . 4 ) 5 6 1 7 ( 7 0 . 7 )
1 class used 906 (55.4) 322 (41.5) 176 (36.2) 30 (14.1) 90 (35.3) 863 (12.7) 1524 (19.2)
2 classes used 545 (33.4) 323 (41.7) 167 (34.4) 101 (47.4) 102 (40.0) 264 (3.9) 619 (7.8)
3 classes used 153 (9.4) 102 (13.2) 113 (23.3) 63 (29.6) 49 (19.2) 68 (1.00) 160 (2.0)
4 classes used 29 (1.8) 27 (3.5) 29 (6.0) 18 (8.5) 13 (5.1) 7 (0.10) 29 (0.36)
5 classes used 1 (0.06) 1 (0.13) 1 (0.21) 1 (0.47) 1 (0.39) 0 1 (0.01)
IQR=interquartile range. Data are number (%) unless otherwise stated.
*Because the analysis of exposure to immunosuppressive agents was time dependent—with patients transitioning from unexposed to exposed (see statistical methods)—fixed
characteristics of each patient who contributed person time to each exposure category are included in every category to which they contributed. Some patients used more than one class of
immunosuppressive drug during follow-up.
†Patients diagnosed with malignancy before cohort entry were excluded from subsequent cohort analysis, but were included in comparisons to general population (because individuals with
pre-existing cancer are included in the vital statistics).
‡Other forms of ocular inflammation consisted of conjunctival inflammatory diseases not associated with mucous membrane pemphigoid, and corneal, orbital, and optic nerve inflammatory
diseases.
§ Not all systemic inflammatory diseases are necessarily related to ocular inflammation. The count for patients with mucous membrane pemphigoid patients refers to systemic inflammatory
diseases in addition to mucous membrane pemphigoid, the latter having been present in 100 of these patients. Many of the patients’ systemic diseases were initially diagnosed and treated
during follow-up, explaining why a large proportion of patients with immune mediated diseases appear in the no immunosuppressive treatment group at some point during follow-up.
¶Because use of immunosuppressive therapy was coded as a time dependent variable, some patients contributing person time to the “unexposed” group went on to receive
immunosuppressive therapy at a later date. The number of classes of agents eventually used by the patients at some point during observation is given here. Except when only one class of
drug was used, the sum of patients in the immunosuppressive drug columns will not add up to the number in the all patients column. Seven patients treated with intravenous
immunoglobulin and none of the other immunosuppressive drugs are not included in any of these categories.
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tion, both for patients unexposed to immunosuppres-
sive therapy (standardised mortality ratio [SMR] 1.02,
95%confidenceinterval[CI]0.94 to1.11;table 2)and
forthecohortasawhole(1.03,0.96to1.10).Similarly,
overall cancer mortality was similar to that of the US
population both for cohort members unexposed to
immunosuppressive drugs (cancer specific SMR 1.10,
95% CI 0.93 to 1.29) and for the whole cohort (1.07,
0.94 to 1.23).
Therelationofimmunosuppressivetherapytoover-
allandcancermortalityissummarisedintables 3and4
(see also fig 2 and fig 3). Non-treatment factors that
were consistently associated with increased mortality
risk in the within cohort comparisons (and were
adjusted for in the models) included increasing age,
African-American race, higher Charlson index score,
activesmoking,andadiagnosisofWegener’sgranulo-
matosis or rheumatoid arthritis. A supplemental table
compares overall and cancer mortality among treated
cohort members with that of the US population using
SMRs (see supplemental table 2), but these findings
are less reliable because vital statistics data only
included information on age, sex, and race, and not
the remaining confounding factors.
After adjusting for confounding, the antimetabolites
as a class of immunosuppressive drugs were not asso-
ciated with a substantial increase in overall mortality
(fully adjusted hazard ratio 1.08, 95% CI 0.86 to 1.37)
orcancermortality(0.89,0.54to1.48).Themostcom-
monly used antimetabolites—azathioprine, metho-
trexate, and mycophenolate mofetil—were not
individually associated with increased risk of overall
or cancer mortality either. The tendency towards
increased crude and demographic adjusted hazard
ratios observed with antimetabolite therapy (see
tables 3 and 4) corresponded to greater use of these
drugs in patients who had systemic inflammatory co-
morbidities and were older.
Likewise, the fully adjusted within cohort compari-
son found no increased overall mortality risk asso-
ciated with T cell inhibitors as a class (fully adjusted
hazard ratio 0.81, 95% CI 0.59 to 1.11). Cancer mor-
tality was not significantly increased with T cell inhibi-
tor therapy either (0.78, 0.38 to 1.59). Overall and
cancer mortality results for ciclosporin individually
hadapatternsimilartothatforTcellinhibitorsingen-
eral.
Alkylating agents as a class were not associated with
significantly increased overall mortality in the within
cohort comparisons (fully adjusted hazard ratio 1.17,
95%CI0.85to1.61),butall-cancermortalitywasnon-
significantly raised (1.74, 0.91 to 3.32). Comparison of
overallandcancermortalitywiththatofthegeneralUS
population gave similar results (SMR 1.06, 95% CI
0.88 to 1.26; cancer-specific SMR 1.42, 95% CI 0.99
to 1.98). Findings for cyclophosphamide followed
similar patterns to those for alkylating agents as a
class. Only 87 patients had been treated with chloram-
bucil, limiting statistical precision for evaluation of its
association with overall and cancer mortality.
TNFinhibitorsinaggregatewereassociatedwithsig-
nificant increases both in overall mortality (fully
adjusted hazard ratio 1.99, 95% CI 1.00 to 3.98) and
cancer mortality (3.83, 95% CI: 1.13 to 13.01). Com-
parisonswithmortalityintheUSgeneralpopulation—
adjusting only for age, sex, and race—yielded similar
results for both overall (SMR 2.62, 95% CI 1.30 to
4.71) and cancer mortality (cancer-specific SMR 4.05,
95% CI 1.28 to 9.53). Estimated risk ratios for etaner-
cept and infliximab were similar in magnitude, but
were non-significant, with a smaller number of obser-
vations. Little information was available about adali-
mumab, which was introduced shortly before 2005.
Sensitivity analyses eliminating patients with systemic
inflammatoryco-morbiditiesdidnotsubstantiallyalter
the SMR for TNF inhibitors, but because all but two
deaths (neither of which was from cancer) were elimi-
nated in this sensitivity analysis, confidence intervals
became very wide. The 11 deaths observed in the
patientsonTNFinhibitorswereallattributedtodiffer-
ent causes. Six of the patients who died after taking
TNFinhibitorshadalsotakenalkylatingagentsduring
observation; formal interaction testing gave some sug-
gestion of an interaction, but the result was not signifi-
cant (fully adjusted hazard ratio for interaction 2.24,
95% CI 0.90 to 5.64).
Systemic corticosteroid therapy was not associated
with increased overall (hazard ratio 1.13, 95% CI
0.96 to 1.33) or cancer mortality (1.02, 0.72 to 1.45)
after adjusting for confounding. Patients exposed to
dapsone likewise had no significant change in overall
(0.92, 0.55 to 1.55) or cancer mortality (0.92, 0.28 to
2.99) in the fully adjusted within cohort analyses. Eva-
luation of potential associations between immunosup-
pressive drugs and lymphoma mortality risk showed
no significant association, but these analyses had low
Table 2 |Risk of overall and cancer mortality in cohort compared with 1999-2005 US general population, standardised for age, race, and sex
Use of immuno-
suppressive agents
Number
of
patients
Median
follow-up
time
Observed
deaths
Total
person
time
Indirectly
standardised
mortality rate per
100 person years
Standardised
mortality ratio
(95% CI)
Cancer
deaths
Indirectly
standardised cancer
mortality rate per
100 person years
Standardised cancer
mortality ratio
(95% CI)
None 6545 5.68 562 46086 0.89 1.02 (0.94 to 1.11) 149 0.22 1.10 (0.93 to 1.29)
Any 2285 5.60 321 17006 0.91 1.04 (0.93 to 1.16) 69 0.20 1.03 (0.80 to 1.31)
Total 7628 6.98 883 63079 0.90 1.03 (0.96 to 1.10) 218 0.22 1.07 (0.94 to 1.23)
Totals are less than sum of treatment categories because some patients received more than one treatment. Total number of patients excludes 329 patients for whom age, race, or sex
(predominantly race) information was missing. Observed deaths and total person time are slightly lower than in table 1 because of exclusion of patients for whom age, race, or sex were
missing for standardised mortality ratio calculations.
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among immunosuppressed individuals in this cohort.
Evaluation of dose-response relations for individual
antimetabolites, T cell inhibitors, alkylating agents,
dapsone, and systemic corticosteroids did not show
increasing risks of overall or cancer mortality with
increasing cumulative dose or across a dose threshold,
or with increasing highest observed dose. The data
were insufficient to evaluate these relations for TNF
inhibitors.
Within cohort survival analyses excluding patients
with systemic inflammatory diseases gave similar
results (see supplemental tables 3 and 4), except that
data were not sufficient to conduct these analyses
meaningfully for TNF inhibitors. Additional sensitiv-
ity analyses undertaken were: (1) exclusion of subsets
of calendar time to address potential cohort effects; (2)
exclusionofthefirstfouryearsoffollow-uptoallowfor
a potential lag in the occurrence of adverse effects of
treatment; (3) exclusion of patients who began follow-
up after 1997 (to address potential concerns that slow
growing tumours may not have caused death during
theperiodofobservation);and(4)exclusionofpatients
withmucousmembranepemphigoidandintermediate
uveitis, who had SMRs significantly different from 1.0
(see supplemental table 2). None of these sensitivity
analysesresultedinqualitativelydifferentconclusions,
and risk ratios were quite similar to those reported
above, except that overall and cancer mortality risk
ratios tended to be closer to 1 for patients treated with
cyclophosphamide before 1998. The available data
were insufficient to perform sensitivity analyses (2) to
(4)forTNFinhibitorsortoperformsensitivityanalysis
(4) for mycophenolate mofetil.
DISCUSSION
This retrospective cohort study of 7957 patients with
ocular inflammation, 2340 of whom were treated with
immunosuppressive drugs, found no significantly
increased risk of death or of death from cancer
among those who had received treatment with anti-
metabolites (predominantly methotrexate, azathiopr-
ine, and mycophenolate mofetil), T cell inhibitors
(predominantlyciclosporin),dapsone,orsystemiccor-
ticosteroids, after adjusting for confounding factors.
Treatment with cyclophosphamide was not associated
withsignificantincreasesinoverallmortality,butthere
was a non-significant suggestion of increased cancer
mortality. Data about treatment with TNF inhibitors
were less methodologically robust than those for
other drugs, but observations of significant increases
in overall mortality and cancer mortality after TNF
inhibitor therapy add to concerns about these treat-
ments, especially in patients also treated with alkylat-
ing agents, and require further investigation.
Strengths and weaknesses of the study design
A principal strength of this study was that the eye dis-
ease indication for use or non-use of immunosuppres-
sion was a non-lethal disease, overcoming the causal
pathwayofindications-for-treatmentbiasaseffectively
as possible outside a randomised trial, which is not a
feasible study design option to address this question.
19
Indications-for-treatmentbiashasbeenarelevantcon-
cern for most previous studies on this topic.
1 Direct
comparison with the US vital statistics verified that
patientsinthisgroupwhowerefreeofsystemicinflam-
matory diseases did not have a significantly increased
risk of overall mortality or cancer mortality. Thus, the
studymethodologydoesseemtoavoidtheproblemof
indications-for-treatment bias. Concerns about enter-
ing both prevalent and incident cases into the study
cohort also are minimised when the disease condition
does not affect the risk of the study outcome.
Ascertainmentof overall and cancer mortality using
the National Death Index was probably excellent.
20-22
The duration of follow-up after exposure was favour-
able for all agents except mycophenolate mofetil and
the TNF inhibitors (the latter of which were associated
with increased risk despite limited follow-up time);
Azathioprine
Methotrexate
Mycophenolate mofetil
Antimetabolite (in aggregate)
Ciclosporin
T cell inhibitor (in aggregate)
Chlorambucil
Cyclophosphamide
Alkylating agent (in aggregate)
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TNF inhibitor (in aggregate)
Dapsone
Systemic corticosteroids
0.99 (0.72 to 1.38)
1.02 (0.78 to 1.34)
0.90 (0.48 to 1.68)
1.08 (0.86 to 1.37)
0.79 (0.57 to 1.10)
0.81 (0.59 to 1.11)
1.43 (0.72 to 2.85)
1.14 (0.81 to 1.60)
1.17 (0.85 to 1.61)
2.18 (0.93 to 5.09)
2.44 (0.90 to 6.62)
1.99 (1.00 to 3.98)
0.92 (0.55 to 1.55)
1.13 (0.96 to 1.33)
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Fig 2 | Adjusted relative hazard of all cause mortality for each
immunosuppressive agent and class of agents studied
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1.13 (0.60 to 2.14)
0.89 (0.48 to 1.63)
0.83 (0.20 to 3.52)
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Fig 3 | Adjusted relative hazard of mortality attributed to
cancer for each immunosuppressive agent and class of agents
studied
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up for mortality did not increase risk ratios, suggesting
that the amount of follow-up time was sufficient to
ascertain overall and cancer mortality for the other
drugs.Because deaths from cancer are typically recog-
nised easily, and because the proportion of mortality
attributed to cancer was as expected, any effect of
miscoding of death certificates on cancer mortality
results was probably small.
Although the study’s ascertainment of immunosup-
pressive drug use (typically administered by the
clinics) was probably excellent during follow-up at
the clinics, some drug exposures before or after the
period of management at participating clinics may
Table 3 |Use of immunosuppressive drugs and risk of overall mortality*
Agent Crude HR (95% CI) P
HR adjusted for age,
race, sex (95% CI) P
HR fully adjusted
model (95% CI) P
No immunosuppressive agent 1.00 1.00 1.00
Antimetabolite (any) 1.60 (1.33 to 1.91) <0.0001 1.23 (1.02 to 1.47) 0.029 1.08 (0.86 to 1.37) 0.50
Azathioprine 1.73 (1.35 to 2.21) <0.0001 1.13 (0.88 to 1.46) 0.33 0.99 (0.72 to 1.38) 0.97
Methotrexate 1.56 (1.25 to 1.95) <0.0001 1.19 (0.95 to 1.49) 0.129 1.02 (0.78 to 1.34) 0.87
Mycophenolate mofetil 0.94 (0.53 to 1.67) 0.82 1.00 (0.56 to 1.78) 0.99 0.90 (0.48 to 1.68) 0.73
T cell inhibitor (any) 0.89 (0.69 to 1.14) 0.35 1.22 (0.95 to 1.56) 0.121 0.81 (0.59 to 1.11) 0.18
Ciclosporin 0.81 (0.63 to 1.05) 0.118 1.17 (0.90 to 1.52) 0.25 0.79 (0.57 to 1.10) 0.16
Alkylating agent (any) 2.36 (1.92 to 2.90) <0.0001 1.26 (1.02 to 1.56) 0.031 1.17 (0.85 to 1.61) 0.34
Chlorambucil 1.33 (0.73 to 2.41) 0.35 1.97 (1.08 to 3.59) 0.027 1.43 (0.72 to 2.85) 0.30
Cyclophosphamide 2.54 (2.05 to 3.14) <0.0001 1.19 (0.96 to 1.49) 0.116 1.14 (0.81 to 1.60) 0.45
TNF inhibitor (any) 1.45 (0.75 to 2.82) 0.27 1.96 (1.01 to 3.81) 0.048 1.99 (1.00 to 3.98) 0.050
Etanercept 1.78 (0.79 to 3.99) 0.16 2.04 (0.91 to 4.59) 0.085 2.18 (0.93 to 5.09) 0.072
Infliximab 1.31 (0.49 to 3.51) 0.59 2.25 (0.83 to 6.05) 0.110 2.44 (0.90 to 6.62) 0.080
Dapsone 3.45 (2.76 to 4.30) <0.0001 0.98 (0.77 to 1.24) 0.85 0.92 (0.55 to 1.55) 0.77
No systemic corticosteroids 1.00 1.00 1.00
Systemic corticosteroids 1.03 (0.90 to 1.19) 0.63 1.24 (1.08 to 1.43) 0.003 1.13 (0.96 to 1.33) 0.15
HR=hazard ratio; CI=confidence interval; TNF=tumour necrosis factor.
*For immunosuppressive agents, each comparison is of person time after exposure to the agent indicated compared with patients never exposed to
any of the agents listed. For corticosteroids, the comparison is of person time after use of systemic corticosteroids versus person time before use of
systemic corticosteroids. Fully adjusted models adjust for age, race, sex, smoking status, site of ocular inflammation, bilaterality of ocular
inflammation, Charlson index score, and indicator variables for those systemic inflammatory diseases that were significantly associated with mortality
in Cox regression. In addition to the agents listed, small numbers of patients taking leflunomide, tacrolimus, sirolimus, and adalimumab were
included in the antimetabolite, T cell inhibitor, and TNF inhibitor groups, respectively.
Table 4 |Use of immunosuppressive drugs and risk of mortality caused by cancer*
Agent Crude HR (95% CI) P
HR adjusted for age,
race, sex (95% CI) P
HR fully adjusted
model (95% CI) P
No immunosuppressive drug 1.00 1.00 1.00
Antimetabolite (any) 1.16 (0.76 to 1.76) 0.49 0.87 (0.57 to 1.32) 0.50 0.89 (0.54 to 1.48) 0.66
Azathioprine 1.73 (1.04 to 2.87) 0.034 1.06 (0.63 to 1.77) 0.83 1.13 (0.60 to 2.14) 0.70
Methotrexate 1.03 (0.60 to 1.76) 0.93 0.76 (0.44 to 1.32) 0.33 0.89 (0.48 to 1.63) 0.70
Mycophenolate mofetil 0.65 (0.16 to 2.66) 0.55 0.67 (0.16 to 2.76) 0.58 0.83 (0.20 to 3.52) 0.80
T cell inhibitor (any) 0.85 (0.51 to 1.44) 0.55 1.15 (0.68 to 1.95) 0.60 0.78 (0.38 to 1.59) 0.50
Ciclosporin 0.88 (0.52 to 1.48) 0.63 1.24 (0.73 to 2.10) 0.42 0.82 (0.40 to 1.67) 0.59
Alkylating agent (any) 2.36 (1.54 to 3.60) <0.0001 1.21 (0.78 to 1.88) 0.39 1.74 (0.91 to 3.32) 0.092
Chlorambucil 1.02 (0.25 to 4.14) 0.97 1.54 (0.38 to 6.27) 0.55 2.29 (0.53 to 9.83) 0.26
Cyclophosphamide 2.54 (1.64 to 3.93) <0.0001 1.14 (0.72 to 1.79) 0.58 1.61 (0.81 to 3.22) 0.17
TNF inhibitor (any) 2.06 (0.65 to 6.55) 0.22 2.44 (0.77 to 7.75) 0.132 3.83 (1.13 to 13.01) 0.031
Etanercept 2.47 (0.60 to 10.06) 0.21 2.51 (0.61 to 10.24) 0.20 4.38 (0.96 to 19.93) 0.056
Infliximab 1.42 (0.20 to 10.26) 0.73 2.13 (0.29 to 15.51) 0.45 2.95 (0.40 to 21.83) 0.29
Dapsone 1.92 (1.06 to 3.47) 0.031 0.55 (0.29 to 1.02) 0.056 0.92 (0.28 to 2.99) 0.89
No systemic corticosteroids 1.00 1.00 1.00
Systemic corticosteroids 0.95 (0.70 to 1.28) 0.72 1.10 (0.81 to 1.49) 0.55 1.02 (0.72 to 1.45) 0.89
HR=hazard ratio; CI=confidence interval; TNF=tumour necrosis factor.
*For immunosuppressive drugs, each comparison is of person time after exposure to the agent compared with patients never exposed to any of the
agents listed. For corticosteroids, the comparison is of person time after use of systemic corticosteroids versus person time before use of systemic
corticosteroids. Fully adjusted models adjust for age, race, sex, smoking status, site of ocular inflammation, bilaterality of ocular inflammation,
Charlson index score, and indicator variables for those systemic inflammatory diseases that were significantly associated with mortality in Cox
regression. In addition to the agents listed, small numbers of patients taking leflunomide, tacrolimus, sirolimus, and adalimumab were included in
the antimetabolite, T cell inhibitor, and TNF inhibitor groups, respectively.
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ficient to mask a true association between drug expo-
sure and mortality, a substantially increased overall
mortalityamongtheunexposedcohortmemberscom-
paredwiththeUnitedStatesgeneralpopulationwould
beexpected,butnosuchpatternwasobserved(table 2).
For most drugs, a large sample size and a substantial
length of follow-up for exposed and unexposed
patients allowed the conduct of a broad array of dose-
response relation analyses and sensitivity analyses,
each of which supported the primary conclusions.
However, for mycophenolate mofetil, chlorambucil,
and TNF inhibitors the available information was less
extensive. Additional follow up or more observations
would be valuable for evaluation of these drugs. For
theTNFinhibitoranalysesinparticular,dose-response
andanalysesexcludingthefirstfouryearsoffollow-up
or requiring long term follow-up were inadequate
becauseofthelimitedextentofobservationsregarding
these newer drugs. However, such analyses are gener-
ally used to unmask effects of high doses or remove
possible “immortal person time” from an analysis,
which would usually increase rather than diminish
risk ratios.
Implications of the study
Patients with ocular inflammation who take azathiopr-
ine, methotrexate, ciclosporin, dapsone, and systemic
corticosteroids most likely do not increase their risk of
mortality or cancer mortality substantially. Longer
term follow-up of the cohort would be valuable to
obtain more data about mycophenolate mofetil, for
whichtheavailablefollow-uptimeiscurrentlylimited,
but the available data do not suggest increased overall
or cancer mortality with this agent. These conclusions
shouldbegeneralisabletootherdiseaseindicationsfor
immunosuppressive treatment unless a disease-treat-
ment interaction that increases the risk of death exists
for other diseases, which seems unlikely.
Wearenotawareofpreviousreportsregardingmor-
tality risk for most of the agents studied. However, our
negative results are broadly consistent with published
work on risk of cancer for the antimetabolites
azathioprine, methotrexate, and mycophenolate
mofetil.
1 One of two previous reports suggested an
increased risk of leukaemia and skin cancers (among
many cancers evaluated) with ciclosporin in patients
who were treated with psoralen and ultraviolet A,
11
whereas our results, from a substantially larger cohort,
suggest that ciclosporin does not increase overall or
cancer mortality risk, consistent with the previous
report regarding mortality.
2 The literature has been
mixed regarding whether systemic corticosteroids
increase the risk of mortality.
5-10 Our results, which
showed increased mortality when patients with sys-
temic inflammatory co-morbidities are included but
no increased mortality risk when they are excluded,
supporttheviewthatsystemiccorticosteroidtreatment
does not itself increase the risk of overall or cancer
mortality, but rather that the systemic disease that
serves as the indication for such treatment increases
mortality in these patients. Likewise, dapsone therapy
does not seem to increase overall or cancer mortality.
Our study of about 500 patients with ocular inflam-
mation treated with alkylating agents showed no sig-
nificant increase in overall mortality. However,
cancer mortality results were less reassuring. Cancer
mortality was not increased to a statistically significant
degree in either the fully adjusted within cohort com-
parisonorthecomparisonwiththegeneralpopulation,
but in each case risk ratios were high and the 95% con-
fidenceintervalsonlynarrowlyincluded1.0.Thus,our
observations could be consistent with a moderate
increase in overall cancer mortality—as suggested by
a minority of previous reports
11213—but cannot be
taken as conclusive without expansion of the cohort.
Potentially increased cancer mortality—which would
probably be cancelled out by survival benefits when
alkylatingagentsareusedtotreatlifethreateningauto-
immunediseasessuchasWegener’sgranulomatosis—
is a clinically important consideration regarding the
use of alkylating agents in non-lethal diseases such as
ocular inflammation. Cyclophosphamide results were
similar to the overall alkylating agent results. Addi-
tional data—especially regarding chlorambucil, for
which we had a limited number of observations—are
needed to better evaluate the overall and cancer mor-
tality risk when these agents are given for inflamma-
tory diseases.
Our data about the recently introduced TNF inhibi-
tors were limited regarding the number of patients
(about 200) and the duration of follow-up (median 2.
8 years). However, the large adverse effects we
observed add to concerns that use of these agents
may substantially increase overall and cancer mortal-
ity. A previous meta-analysis of randomised trial data,
which showed increased risk of cancer with TNF inhi-
bitor therapy with a dose-response pattern,
14 is consis-
tent with our findings. However, our findings are
inconsistent with those of four large observational stu-
diesofpatientswithrheumatoidarthritisover substan-
tiallylongerperiods
315-17andonestudyofpatientswith
Crohn’s disease,
18 each of which found no increased
overall cancer risk, with risk ratios close to 1.0. It has
previously been proposed that TNF inhibitors may
acceleratetheclinicalcourseofpre-existingbutsubcli-
nical cancers, but may not initiate cancer.
14 If so, an
initially increased risk of clinically manifest cancer
should be diluted with a longer duration of follow-up,
which would be consistent with the available publica-
tions and our results. Readers should recognise that
our TNF inhibitor results are less robust than the
results for the other agents. A large proportion of our
patients treated with TNF inhibitors had associated
systemic inflammatory diseases which may have
increased their mortality risk. We had limited ability
to conduct critical sensitivity analyses to verify our
results, and the results are of marginal statistical signif-
icance in a study where multiple comparisons were
performed. Therefore, we do not believe these results
tobeconclusive.However,theapparentstrengthofthe
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evaluation of the potential risks of these widely used
agents, including further evaluation of the possibility
that TNF inhibitors and alkylating agents in combina-
tion or in succession increase mortality risk, as has
been suggested in a previous report.
26
In summary, our results suggest that methotrexate,
azathioprine, mycophenolate mofetil, ciclosporin,
dapsone,andsystemiccorticosteroidsgiventopatients
with ocular inflammatory diseases do not increase the
risk of overall or cancer mortality. Alkylating agents
didnotsignificantlyincreasethe riskofoverallmortal-
ity, but our results could be consistent with a small to
moderate increase in cancer mortality risk with these
agents.Ourfindingssuggestingsubstantiallyincreased
overall and cancer mortality after TNF inhibitor ther-
apyshouldnotbetakenasconclusiveunlesssupported
by more data covering a longer period of time.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Few data are available about whether overall mortality or cancer mortality is raised after
treatment with immunosuppressive agents for inflammatory diseases
Some findings suggest thatoverall cancer incidence may beincreasedwith alkylatingagents
and with tumour necrosis factor (TNF) inhibitors, but most reports suggest that it is not
substantially raised with the other agents
WHAT THIS STUDY ADDS
Use of antimetabolites, T cell inhibitors, dapsone, and systemic corticosteroids does not
seem to increase overall or cancer related mortality.
Use of alkylating agents was not associated with increased overall mortality, but cancer
related mortality was non-significantly increased.
Preliminary data suggest that overall and cancer mortality may be increased with TNF
inhibitors; these findings should be confirmed in additional studies in view of
methodological limitations of our study for this drug class.
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